On August 29, 2018 Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, reported that Michael Mulroy, President and Chief Executive Officer, will participate in a panel discussion at the B. Riley FBR Healthcare Conference at 8:20am ET/5:20 am PT on Tuesday, September 4, 2018 in New York (Press release, , AUG 29, 2018, View Source;date=August+29%2C+2018&title=Asterias+Biotherapeutics%E2%80%99+CEO+Michael+Mulroy+to+Participate+on+Regenerative+Medicine+Therapies+Panel+at+the+B.+Riley+FBR+Healthcare+Conference [SID1234529206]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The discussion will be moderated by George Zavoico, Senior Research Analyst, SVP Equity Research, B. Riley FBR and the other panelists will include senior executives from other regenerative medicine therapies companies.

Mr. Mulroy will be meeting with investors throughout the conference and one-on-one meetings may be scheduled through the B. Riley 1×1 desk or by contacting Michael Polyviou, at 732-933-2754 or [email protected].